Related Experiment Videos
Fatal angioedema associated with lisinopril
1Dameron Hospital Pharmacy, Stockton, CA.
The Annals of Pharmacotherapy
|October 1, 1992
Summary
Fatal angioedema occurred in a patient taking lisinopril, an angiotensin-converting enzyme (ACE) inhibitor. This case highlights the severe, life-threatening risks of ACE inhibitors, emphasizing the need for prompt medical attention for swelling or breathing difficulties.
Area of Science:
- Cardiology
- Pharmacology
- Emergency Medicine
Background:
- Angiotensin-converting enzyme (ACE) inhibitors are widely prescribed for hypertension and heart failure.
- Angioedema is a known, albeit rare, adverse effect of ACE inhibitors.
- Longer-acting ACE inhibitors like lisinopril are increasingly used, raising concerns about this adverse reaction.
Observation:
- A 66-year-old male presented with throat swelling and dyspnea after starting lisinopril.
- Despite aggressive treatment, he developed complete airway obstruction requiring emergency tracheotomy.
- Hypoxic ischemic encephalopathy followed cardiopulmonary arrest, leading to death.
Findings:
- This case illustrates a fatal outcome from lisinopril-induced angioedema.
- ACE inhibitor-associated angioedema is a class-related, potentially lethal adverse event.
- The severity of the reaction underscores the importance of early recognition and intervention.
Implications:
- Clinicians must be vigilant for angioedema in patients on ACE inhibitors.
- Prompt emergency evaluation is crucial for unexplained throat swelling or breathing issues.
- Patient education on reporting symptoms immediately is vital to prevent severe outcomes.